SECTION OF HEMATOLOGY 3rd International Conference LEUKEMIA 2014 Santa Margherita Ligure - Portofino May 21–24, 2014 Chairmen Angelo M. Carella Felicetto Ferrara Enrica Morra 3rd International Conference LEUKEMIA 2014 This Conference will be dedicated to Prof. John M. Goldman PRESENTATION The Conference, with the participation of the most important International and Italian experts, wants to provide an update on the most innovative aspects of cellular and molecular biology, treatment of acute and chronic leukemias, myelodysplastic syndromes and Ph-negative chronic myeloproliferative syndrome. One section will be dedicated to the new drugs in onco-hematology. ADDRESSED TO Physicians specialized in Hematology, Oncology and Biologists. OFFICIAL LANGUAGE The meeting will be held in English. No simultaneous translation will be provided. 2 PROGRAMME WEDNESDAY, MAY 21 CHALLENGES IN PHILADELPHIAPOSITIVE LEUKEMIAS NEW DRUGS IN ONCO-HEMATOLOGY (not for CME credits) Chairmen: Robin Foà Angelo M. Carella Chairmen: Massimo Federico Pier Luigi Zinzani 16.30 Introduction Robin Foà 14.00 Celgene pipeline and in earlydevelopment programs James Carmichael 16.35 Current clinical options in Ph+ ALL Robin Foà 14.15 Novelties in strategic approach to chronic hematological malignancies Alf Bernhardt 16.50 Early and deep molecular response predictive of long term outcome in Ph+ leukemias Giovanni Martinelli 14.30 An update of Brentuximab Vedotin and its future prospective Andreas Engert 17.05 14.45 New perspectives in acute leukemias Giovanni Martinelli Ponatinib: bridge to transplant and post transplant clinical strategies Fabio Ciceri 17.20 15.00 Arsenic trioxide: many stories about an old product Giuseppe Rossi Conclusions and general discussion Angelo M. Carella 17.30 Round Table BONE MARROW TRANSPLANTATION IN LEUKEMIAS: NEW PERSPECTIVES 15.15 New prospective in hematology Daniele Alberti 15.30 The use of an adaptive trial design in a phase III trial of Vosaroxin and Cytarabine in relapsed and refractory AML Adam Craig 16.00 New drugs anti-leukemia Danilo Perrotti Chairmen: Alberto Bosi Andrea Bacigalupo Immunologic pressure after transplant and HLA Fabio Ciceri 3 19.00 Unrelated donor transplant for leukemia Jane F. Apperley 9.20 Optimal non-transplant post remission therapy Jacob M. Rowe Finding a donor for most eligible patients William Arcese 9.40 Allogeneic transplant for older patients: GITMO experience Alessandro Rambaldi HDCT in MDS: indications, timing and optimization of the results. What’s new? Emanuele Angelucci 10.00 Therapy of a fit 70 years old individual Richard F. Schlenk 10.20 APL in 2014: next challenges for the final cure Francesco Lo Coco 10.40 Conclusions and general discussion Sergio Amadori 10.45 Coffee break 11.00 Plenary Lecture Regulation of self renewal in cancer stem cells Pier Giuseppe Pelicci Presented by: Roberto M. Lemoli End of session THURSDAY, MAY 22 8.00 Opening Ceremony ACUTE MYELOID LEUKEMIAS IN 2014: SOME UNRESOLVED ISSUES Chairmen: Jacob M. Rowe Sergio Amadori 8.15 Introduction Jacob M. Rowe 8.20 The increasing role of mutations and genomics Brunangelo Falini 8.40 9.00 4 The increasing clinical relevance of minimal residual disease Gert J. Ossenkoppele Is there a role of adjunctive therapy to standard 3+7? Alan K. Burnett SEPSIS AND SEPTIC SHOCK IN HEMATOLOGICAL NEOPLASIAS Chairman: Francesco Menichetti 11.30 Pathophysiology and clinical features Valerio Del Bono 11.50 Infections with multidrugresistant pathogens Gian Maria Rossolini 12.10 Neutropenic Enterocolitis: a life threatening complications Edoardo Benedetti 12.30 IgM concentrated: rationale for its use in hematology in the era of “bad bugs” Fabio Tumietto 12.50 13.15 16.30 Ultra-high risk patients: definition and treatment pathway in the era of novel drug landscape Peter Dreger 16.50 Break 17.10 IgM enriched immunoglobulins and defribotide after allogenic hematopoietic transplantation in acute leukemia Giuseppe Milone Second line therapy: what are the options today? Véronique Leblond 17.30 Immunotherapeutic strategies including transplant John G. Gribben Lunch 17.50 A look at the future: new options? George Follows 18.10 Conclusions and general discussion Enrica Morra, Giovanni Pizzolo CHRONIC LYMPHOCYTIC LEUKEMIA Chairmen: Enrica Morra Giovanni Pizzolo 15.00 Introduction Manlio Ferrarini 15.10 NoTCH1 mutations: pathogenesis and clinical significance Davide Rossi 15.30 15.50 16.10 Transforming response prediction to chemo-immunotherapy using genome technologies Anna Schuh Do the next molecular markers have an impact in treatment strategy? Gianluca Gaidano First line therapy: which are the options today? Marco Montillo FRIDAY, MAY 23 CHRONIC MYELOID LEUKEMIAS: WHAT IS NEW? Chairmen: Rudiger Hehlmann Angelo M. Carella 8.00 Introduction Rudiger Hehlmann 8.05 The basis for clinical heterogeneity Giuseppe Saglio 8.25 Initial choice of therapy Michele Baccarani 5 8.45 Molecular monitoring Andreas Hochhaus 9.05 9.25 9.45 11.50 Alternative approaches in eradicating the malignant clone Richard A. Van Etten New markers for the diagnosis of ALL: including NGS? Robin Foà / Sabina Chiaretti 12.10 Early molecular response is predictive of long-term outcome? Susan Branford Minimal residual disease: comparison of different methods Monika Brüggemann 12.30 Current clinical options after resistance/intolerance to 1G/2G TKIs Fabrizio Pane Current treatment results without antibodies Renato Bassan 12.50 Antibody therapy Dieter Hoelzer 10.05 Blastic crisis management Rudiger Hehlmann 13.10 Targeted therapy Oliver G. Ottmann 10.25 When should we transplant? Jane Apperley 13.30 Lunch Coffee break 15.00 10.45 11.00 Safety profiles of different TKIs Carlo Gambacorti-Passerini Risk factors and therapy in adult T-ALL Vahid Asnafi 15.20 How will we manage CML in the next decade? Stephen O’Brien Stem cell transplantation Andrea Bacigalupo 15.40 Conclusions and general discussion Angelo M. Carella Conclusions and general discussion Felicetto Ferrara 16.00 Break 11.20 11.40 NEW MOLECULAR INSIGHTS AND THERAPEUTIC STRATEGIES IN ACUTE LYMPHOCYTIC LEUKEMIA Chairmen: Dieter Hoelzer Felicetto Ferrara 11.45 6 Introduction Dieter Hoelzer MYELODYSPLASTIC SYNDROMES Chairmen: Giorgina Specchia Pellegrino Musto 16.15 Introduction Giorgina Specchia 16.20 Classification Pellegrino Musto 16.40 Prognostic models to predict survival Valeria Santini 17.00 Low-risk patients with deletions in chromosome 5 Esther N. Oliva 9.50 Therapeutic challenges in PV and ET patients conventionally classified at low-risk for thrombosis Tiziano Barbui 10.10 Prefibrotic myelofibrosis: a diagnosis that counts Giovanni Barosi 10.30 Are we ready for treatment recommendations with Ruxolitinib in myelofibrosis? Jean-Jacques Kiladjian 17.20 Therapeutic strategies Giorgina Specchia 17.40 Five years after Azacitidine approval: remaining challenges Thomas Prebet 18.00 Who should be transplanted and when? Maria Teresa Voso 10.50 Deciding hematopoietic stemcell transplant in myelofibrosis Nicolaus Kröger 18.20 Conclusions and general discussion Pellegrino Musto 11.10 Conclusions and general discussion Marco Gobbi 11.40 End of the conference SATURDAY, MAY 24 PH-NEGATIVE MYELOPROLIFERATIVE SYNDROMES Chairmen: Tiziano Barbui Marco Gobbi 9.00 Introduction Tiziano Barbui 9.10 Molecular diagnosis of MPNs in practice Robert Kralovics 9.30 Molecular prognostic profiling in primitive myelofibrosis Alessandro Vannucchi 7 SCIENTIFIC COORDINATORS Angelo Michele Carella U.O.C. Ematologia I IRCCS A.O.U. San Martino-IST Genova (I) Felicetto Ferrara U.O. Ematologia e Trapianto di Midollo Osseo A.O. A. Cardarelli Napoli (I) Enrica Morra U.O. Ematologia e Trapianto di Midollo A.O. Ospedale Niguarda Cà Granda Milano (I) SPEAKERS AND CHAIRMEN Daniele Alberti, Origgio, MI (I) Sergio Amadori, Roma (I) Emanuele Angelucci, Cagliari (I) Jane F. Apperley, London (UK) William Arcese, Roma (I) Vahid Asnafi, Paris (F) Michele Baccarani, Bologna (I) Andrea Bacigalupo, Genova (I) Tiziano Barbui, Bergamo (I) Giovanni Barosi, Pavia (I) Renato Bassan, Venezia (I) Edoardo Benedetti, Pisa (I) Alf Bernhardt, Basel (CH) Alberto Bosi, Firenze (I) Susan Branford, Adelaide (AUS) Monika Brüggemann, Kiel (D) Alan K. Burnett, Cardiff (UK) James Carmichael, Seville (S) Sabina Chiaretti, Roma (I) Fabio Ciceri, Milano (I) Adam Craig, South San Francisco (USA) Valerio Del Bono, Genova (I) Peter Dreger, Heidelberg (D) Andreas Engert, Cologne (D) Brunangelo Falini, Perugia (I) Massimo Federico, Modena (I) 8 Manlio Ferrarini, Genova (I) George Follows, Cambridge (UK) Robin Foà, Roma (I) Gianluca Gaidano, Novara (I) Carlo Gambacorti-Passerini, Monza (I) Marco Gobbi, Genova (I) John G. Gribben, London (UK) Rudiger Hehlmann, Heidelberg (D) Andreas Hochhaus, Jena (D) Dieter Hoelzer, Frankfurt (D) Jean-Jacques Kiladjian, Paris (F) Robert Kralovics, Vienna (A) Nicolaus Kröger, Hamburg (D) Véronique Leblond, Paris (F) Roberto M. Lemoli, Genova (I) Francesco Lo Coco, Roma (I) Giovanni Martinelli, Bologna (I) Francesco Menichetti, Pisa (I) Giuseppe Milone, Catania (I) Marco Montillo, Milano (I) Pellegrino Musto, Rionero in Vulture, PZ (I) Stephen O’Brien, Newcastle (UK) Esther Natalie Oliva, Reggio Calabria (I) Gert J. Ossenkoppele, Amsterdam (NL) Oliver G. Ottmann, Frankfurt (D) Fabrizio Pane, Napoli (I) Pier Giuseppe Pelicci, Milano (I) Danilo Perrotti, Baltimore (USA) Giovanni Pizzolo, Verona (I) Thomas Prebet, Marseille (F) Alessandro Rambaldi, Bergamo (I) Davide Rossi, Novara (I) Giuseppe Rossi, Brescia (I) Gian Maria Rossolini, Siena (I) Jacob M. Rowe, Jerusalem (IL) Giuseppe Saglio, Orbassano, TO (I) Valeria Santini, Firenze (I) Richard F. Schlenk, Ulm (D) Anna Schuh, Oxford (UK) Giorgina Specchia, Bari (I) Fabio Tumietto, Bologna (I) Richard A. Van Etten, Orange CA, (USA) Alessandro M. Vannucchi, Firenze (I) Maria Teresa Voso, Roma (I) Pier Luigi Zinzani, Bologna (I) CME Based on Italian regulations, Accademia Nazionale di Medicina (provider n. 31) will assign 16,5 CME credits to the activity 31-86981. The Meeting is addressed to Physicians specialized in Hematology, Oncology and Biologists. It will not be possible to give Credits to physicians specialized in different fields. The credit certification is subject to: - attendance at the entire Meeting - the completion of the Meeting evaluation form - the completion of the final questionnaire (at least 75% of correct answers) REGISTRATION The registration fee is € 150,00 tax free. To register, please send: - registration form duly filled out (even when sponsored by a Pharmaceutical Company) - privacy statement and consent regarding personal information (back of the form) - payment to Accademia Nazionale di Medicina – Via Martin Piaggio 17/6 - 16122 Genova fax 010 83794260 – email: [email protected], by May 12, 2014 Online registration is possible on the website www.accmed.org By submitting the form and the payment, your registration is completed with the exception of specific decisions of the Meeting Secretariat. Incomplete registration will not be admitted. The registration will be confirmed by e-mail, please indicate your e-mail address on the registration form. Cancellation - If the participants minimum number is not reached, Accademia Nazionale di Medicina will advise by a written communication and proceed with the total refund of the fee. - In order to cancel please give advise with a written communication to Accademia Nazionale di Medicina within 10 days from the beginning. A 70% of the registration fee will be returned. Cancellations after that deadline will not be refounded. 9 VENUE PROMOTED BY Grand Hotel Miramare Via Milite Ignoto, 30 Santa Margherita Ligure (GE), Italy ACCADEMIA NAZIONALE DI MEDICINA How to reach the meeting venue: By train the nearest train station is Santa Margherita Ligure, located 1,5 km from the meeting venue. By car From A12 motorway please take “Rapallo” exit an then follow signs to Santa Margherita Ligure (about 5 km) and continue on the road along the seaside. Grand Hotel Miramare is located just a few meters after S. Margherita port. By plane Genoa airport is located 30 km away from the meeting venue. 10 www.accmed.org General Manager: Stefania Ledda ORGANIZING PARTNER Forum Service Via Martin Piaggio 17/6 16122 Genoa Information and registration Ph. +39 010 83794233 Fax +39 010 83794260 [email protected] Hotel booking Ph. +39 010 83794233 Fax +39 010 83794261 [email protected] WITH THE PATRONAGE OF Società Italiana di Ematologia - SIE Società Italiana di Ematologia Sperimentale - SIES 11 With the unconditioned contribution of Platinum Sponsor Gold Sponsor ® Silver Sponsor Bronze Sponsor